Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update – GlobeNewswire

Related Articles:

• There’s gold in them tha brains November 10, 2019   It feels as though novel potential therapies for Parkinson’s are being proposed with an ever increasing frequency. And just when I think there must be few other ways of attacking the condition, a new method is proposed. Recently a biotech firm called Clene Nanomedicine presented data on one such new approach. The experimental treatment is called CNM-Au8 and it…
• Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update - BioSpace December 31, 2020 Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update  BioSpace
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly research review – October 2019 October 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Potential Therapy for Dopaminergic Neurons, CNM-Au8, Enter Phase 2 Trial in Parkinson’s Patients October 29, 2019 CNM-Au8, an investigational therapy by Clene Nanomedicine, improved the survival of dopaminergic neurons, helped prevent loss of mitochondria, and rescued motor function in a rat model of Parkinson’s disease, a study reports. The effects of CNM-Au8 will now be assessed in an open-label (no placebo group) Phase 2 trial, called REPAIR-PD (NCT03815916). This pilot study is enrolling up to 24…
• Dosing Begins in Phase 2 Trial of CNM-Au8, Potential Therapy for Dopaminergic Neurons December 6, 2019 A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients, the therapy’s developer, Clene Nanomedicine, announced. The open-label REPAIR-PD (NCT03815916) clinical trial is enrolling up to 24 people, ages 30 to 80 and diagnosed within the past three years, at its one site at the University of Texas Southwestern Medical Center. “We are excited to…
• Parkinson’s Foundation Launches New Brand, Website Following Merger October 23, 2017 Following the recent merger of the National Parkinson Foundation and the Parkinson’s Disease Foundation, the newly created Parkinson’s Foundation has launched a new brand and website as part of its mission to help those living with Parkinson’s disease (PD). The new website is www.parkinson.org. John Kozyak, chair of the National Parkinson Foundation, said the merger would allow two giants to work together…
• Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger October 30, 2017 The Parkinson’s Foundation recently announced a merger with the Melvin Yahr International Parkinson’s Disease Foundation, a New York-based organization named after Melvin D. Yahr, MD, a pioneer in Parkinson’s disease (PD) research whose work led to the adoption of levodopa as an innovative treatment. The merger will be finalized following approval by the New York Attorney General or Supreme Court. “The…
• Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8 - P&T Community October 24, 2019 Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8  P&T Community
• Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8 - Yahoo Finance October 24, 2019 Clene Nanomedicine Presents New Neuroprotection Data in Parkinson's Disease with Lead Nanocatalytic Therapeutic, CNM-Au8  Yahoo Finance
• Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide insight into potential disease modifying effects of CNM-Au8 for the treatment of ALS patients - BioSpace December 10, 2020 Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide insight into potential disease modifying effects of CNM-Au8 for the treatment of ALS patients  BioSpace
• Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease - BioBuzz January 19, 2021 Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease  BioBuzz
• Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
• Merger of New Mexico Parkinson’s Coalition, PMDAlliance Expected to Improve Patient Services December 14, 2018 The recent merger of the New Mexico Parkinson’s Coalition (NMPC) and national nonprofit Parkinson & Movement Disorder Alliance (PMDAlliance) is expected to significantly boost support services for Parkinson’s patients in the New Mexico area, according to the organizations. “I’m a firm believer in mergers when the organizations share similar missions and are compatible in their purpose and goals,” Sarah Jones, CEO of…
• Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis - GlobeNewswire December 15, 2020 Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis  GlobeNewswire
• Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics - GlobeNewswire December 23, 2020 Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics  GlobeNewswire
• Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecast (2021 - 2026) - GlobeNewswire January 20, 2021 Healthcare Nanotechnology (Nanomedicine) Market - Growth, Trends, and Forecast (2021 - 2026)  GlobeNewswire
• Prevail lands on a Lilly pad December 15, 2020 # # # # 2020 has been a dreadful year for most of the world – burdened by the outbreak and consequences of COVID-19. Despite this, there has been a steady stream of biotech acquisitions related to Parkinson’s which have helped to keep morale high in the PD research community. In October alone, we saw the Portuguese pharmaceutical company Bial…
• Adamas Completes Acquisition of OSMOLEX ER®Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition - BioSpace January 5, 2021 Adamas Completes Acquisition of OSMOLEX ER®Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition  BioSpace
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…